Skip Nav Destination

First Edition

Brief Report January 15 2025

New leads to enhance Tagraxofusp efficacy in pDC-AML

Morgane Boichut,Margaux Poussard,Xavier Roussel,Imane Belakri,Sabeha Biichle,Maxime Fredon,Florian Renosi,Romain Boidot,Olivier Adotevi,Christopher Brooks,Francine Garnache-Ottou,Fanny Angelot Delettre

View article

Supplementary data

Brief Report December 28 2024

Outcomes of Follicular Lymphoma with Leukemic Phase in the Modern Era: Results from a Large Multicenter Study

View article

Supplementary data

Brief Report December 28 2024

Real-World Safety Profile of therapy with Ibrutinib or Acalabrutinib in patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Ramsay Hafer,Francesco Iadevaia,Thomas Z. Rohan,Teresa Duong,Maria Poluch,Gina Keiffer,Michael Li,Andres Ferber,Luca Laurenti,Alan S Khoo,Pierluigi Porcu

View article

Supplementary data

Research Article December 26 2024

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Bei Wang,Benjamin A. Derman,Madina Sukhanova,Daniel Appelbaum,John Cursio,Wei Zhang,Andrzej Jakubowiak,Brian C.-H. Chiu

View article

Research Article December 13 2024

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Zhuoer Xie,Najla Al Ali,Ling Zhang,Peter Papenhausen,Virginia Olivia Volpe,Onyee Chan,Andrew Kuykendall,Seongseok Yun,Alison Walker,Kendra Sweet,Jeffrey E. Lancet,Eric Padron,David A. Sallman,Rami S. Komrokji

View article

Supplementary data

Review Article December 4 2024

Safety Landscape of Bispecific Antibody Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Rodrigo Fonseca,Alex J. Liu,Blake T. Langlais,Diana Almader-Douglas,Holenarasipur R. Vikram,Talal Hilal

View article

Supplementary data

Research Article November 28 2024

Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19 CAR T Cell Therapy in BCP-ALL

Willem P.J. Cox,Noel M.M. Dautzenberg,Linde Dekker,Tesa Klenovsek,Annelisa M. Cornel,Marliek van Hoesel,Dorette S. van Ingen Schenau,Reno S. Bladergroen,Roland P. Kuiper,Laurens T. van der Meer,Friso G. Calkoen,Stefan Nierkens,Frank N. van Leeuwen

View article

Research Article November 25 2024

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Olivia M. Depies,Qianqian Guo,Yuan Gao,Sutapa Sinha,Zhenqing Ye,Weiguo Han,Kari G. Rabe,Mingma S. Hoel,Heather C. Darby,Chuanhe Yu,Esteban Braggio,Sameer A. Parikh,Susan L. Slager,Neil E. Kay,Zhiquan Wang

View article

Supplementary data

Research Article October 24 2024

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

View article

Supplementary data

Research Article October 24 2024

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Son Tran,Patrick Sipila,Melanie M. Frigault,Beatrix Stelte-Ludwig,Amy J. Johnson,Joseph Birkett,Raquel Izumi,Ahmed Hamdy,Ranjan Maity,Nizar J. Bahlis,Paola Neri,Aru Narendran

View article

Supplementary data

First Edition

New leads to enhance Tagraxofusp efficacy in pDC-AML

Outcomes of Follicular Lymphoma with Leukemic Phase in the Modern Era: Results from a Large Multicenter Study

Real-World Safety Profile of therapy with Ibrutinib or Acalabrutinib in patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Safety Landscape of Bispecific Antibody Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19 CAR T Cell Therapy in BCP-ALL

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

ASH Publications

American Society of Hematology

First Edition

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only